Table 1.
Clinicopathological features of patients with or without gain of MYC copy number.
| Normal MYC CN (CN = 2) |
High MYC CN (CN > 2) |
P-value | |
|---|---|---|---|
| Number of Patients | 21 | 59 | — |
| Age, Median (IQR) | 60.5 (51.1–72.5) | 65.2 (53.3–76.4) | 0.240 |
| Male, No. (%) | 10 (47.6%) | 35 (59.3%) | 0.444 |
| AJCC stage | 0.511 | ||
| Stage IIA, No. (%) | 2 (9.5%) | 2 (3.4%) | |
| Stage IIB, No. (%) | 10 (47.6%) | 22 (37.3%) | |
| Stage IIIA, No. (%) | 7 (33.3%) | 20 (33.9%) | |
| Stage IIIB, No. (%) | 2 (9.5 %) | 8 (13.6%) | |
| Stage IIIC, No. (%) | 0 (0%) | 3 (5.1%) | |
| Stave IV, No. (%) | 0 (0%) | 4 (6.8%) | |
| Dominant cell types | |||
| Spindle, No. (%) | 18 (85.7%) | 39 (66.1%) | 0.101 |
| Epithelioid, No. (%) | 3 (14.3%) | 20 (33.9%) | |
| Pigmentation | |||
| Minimal, No. (%) | 18 (85.7%) | 21 (35.6%) | <0.001 |
| Marked, No. (%) | 3 (14.3%) | 38 (64.4%) | |
| Mitotic count | |||
| 0–5/HPF, No. (%) | 21 (100%) | 42 (71.2%) | 0.021 |
| 5–10/HPF, No. (%) | 0 (0%) | 11 (18.6%) | |
| >11/HPF, No. (%) | 0 (0%) | 6 (10.2%) | |
| Basal diameter(clinical), Median (IQR), mm | 15.9 (13.2–17.0) | 17.0 (15.1–18.0) | 0.040 |
| Basal diameter (pathological), Median (IQR), mm | 15.5 (12.0–18.0) | 17.0 (15.0–20.0) | 0.094 |
| Tumor thickness, Median (IQR), mm | 10.0 (8.4–12.0) | 11.0 (8.7–12.2) | 0.390 |
| GNAQ/11 mutation, No. (%) | 19 (90.5%) | 55 (93.2%) | 0.650 |
| BAP1 mutation, No. (%) | 3 (14.3%) | 32 (54.2%) | 0.002 |
| EIF1AX mutation, No. (%) | 10 (47.6%) | 0 (0%) | <0.001 |
| SF3B1 mutation, No. (%) | 3 (14.3%) | 15 (25.4%) | 0.373 |
CN = copy number, IQR = interquartile range, No. = Number AJCC = American Joint Committee on Cancer.